Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT02570776
Other study ID # PK-13-01
Secondary ID
Status Recruiting
Phase N/A
First received May 7, 2014
Last updated October 5, 2015
Start date December 2013
Est. completion date February 2016

Study information

Verified date October 2015
Source National Institute of Liver & GI Diseases, Pakistan
Contact n/a
Is FDA regulated No
Health authority Pakistan: Research Ethics Committee
Study type Observational

Clinical Trial Summary

The prevalence of H. pylori infection in Pakistan is unknown and investigators want to assess it in dyspeptic patients utilizing UBT. At the same time investigators want to validate UBT sensitivity and specificity in Pakistani patients


Description:

The non-invasive methods for the diagnosis of Hp are the Urea Breath Test (UBT) and serological tests. The serological tests includes ELISA test in serum for Hp antibody and in stool for Hp antigen. Serum ELISA Hp antibody is not sensitive for showing active infection and the titres do not decrease even after successful eradication. Serology test cannot be used for those who have previously been treated for Hp, as the decline in titre of Hp antibodies is too slow to be of practical use. The stool Hp antigen detection test is more sensitive and specific as it detects bacterial antigens which will only be positive in the presence of Hp. However, it is cumbersome to collect stool and laboratory services are required. The C14 Urea Breath Test (UBT) is an office based test with sensitivity and specificity comparable to that of the stool antigen test. The diagnostic validity of these tests depends on the prevalence of H pylori infection. A higher prevalence would be associated with higher sensitivity and lower specificity. The safety profile of the urea breath test is very favourable, and no major side effects are associated with it. The aims of this study are to estimate H pylori prevalence in Pakistan among the adult dyspeptic population and to validate the sensitivity and specificity UBT in our population


Recruitment information / eligibility

Status Recruiting
Enrollment 200
Est. completion date February 2016
Est. primary completion date December 2015
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Male and female subjects with dyspeptic symptoms (B1 Criteria of FD)

- Subject who has not been treated for H pylori eradication in the past

- Age above 18 years

- No Alarm symptoms of :

- Gastrointestinal Bleeding

- Anemia

- Early satiety

- Unexplained weight loss

- Progressive dysphagia

- Odynophagia

- Recurrent vomiting

- Family history of GI malignancy

- Previous GI malignancy

Exclusion Criteria:

- Pregnant females

- Use of NSAIDs

- Use of anti- secretory agent (H2 blockers) and proton pump inhibitors in previous 4 weeks

- Use of anti- microbial agents (Clarithromycin, Metronidazole, Amoxacillin, quinalones) or bismuth in last 4 weeks

- .Gastric and/or duodenal erosions or ulcers, polyps or malignancy if noted on endoscopy will be excluded.

- Patients with predominant symptoms or gastro esophageal reflux disease (GERD) or Endoscopic evidence of esophagitis.

- Patients with abnormal upper abdominal ultrasound.

Study Design

Observational Model: Cohort, Time Perspective: Prospective


Related Conditions & MeSH terms


Locations

Country Name City State
Pakistan National Institute of Liver & GI Diseases, Dow University of Health Sciences Karachi Sindh

Sponsors (2)

Lead Sponsor Collaborator
National Institute of Liver & GI Diseases, Pakistan Abbott

Country where clinical trial is conducted

Pakistan, 

Outcome

Type Measure Description Time frame Safety issue
Primary Prevalence of H pylori infection in Pakistani polulation Prevalence of H pylori will be assessed by UBT & confirmed with histopathology as gold standard & sensitivity & specificity will be calculated. 1 day No
Secondary Sensivity & specificity of Heliprobe (C14 UBT system) in local population Sensitivity & specificity will be measured by number of subjects positive based on ROC 1 day No
See also
  Status Clinical Trial Phase
Recruiting NCT06094062 - Smartphone App-assisted PPI N/A
Completed NCT03941288 - Efficacy and Safety of Cannabidiol for Gastroparesis and Functional Dyspepsia Phase 2
Completed NCT04429802 - The Effect of Prucalopride (Resolor®) on Gastric Motor Function and Gastric Sensitivity N/A
Not yet recruiting NCT06369753 - Visible Abdominal Distension N/A
Withdrawn NCT02863822 - Study to Evaluate Dietary Modification in Patients With Functional Dyspepsia. N/A
Recruiting NCT00978159 - Esomeprazole or Famotidine in the Management of Aspirin Related Non-Ulcer Dyspepsia Phase 4
Completed NCT00723502 - Efficacy and Safety Study of Finafloxacin Used in Helicobacter Pylori Infected Patients Phase 2
Completed NCT00148603 - Montelukast in the Treatment of Duodenal Eosinophilia N/A
Completed NCT00217347 - Evaluation of Efficiency of Esophageal Capsule Endoscopy in the Screening of Patients With Gastroesophageal Reflux Disease or Dyspepsia as Compared to Upper Endoscopy N/A
Terminated NCT00220844 - Tricyclic Antidepressants (TCAs) on Gastric Emptying N/A
Completed NCT00232102 - Extension Study to Assess the Long-Term Safety of Tegaserod in Women With Symptoms of Dyspepsia Phase 3
Completed NCT00164996 - Ultrathin Versus Conventional Esophagogastroduodenoscopy in Unsedated Patient With or Without Local Pharyngeal Anaesthesia Phase 3
Completed NCT00232037 - Extension Study to Assess the Long-Term Safety of Tegaserod in Women With Symptoms of Dyspepsia Phase 3
Completed NCT00110968 - Long-term Safety and Efficacy of Itopride Hydrochloride (HCl) in Patients Suffering From Functional Dyspepsia Phase 3
Recruiting NCT05718960 - Traditional Dietary Advice Versus Reassurance-alone in Postprandial Functional Dyspepsia N/A
Terminated NCT04247100 - A Study of Randomized Sham-control Auricular TENS Unit Stimulation in Pediatric Functional Gastrointestinal Disorders N/A
Completed NCT05750641 - The Efficacy of Removal of Animal Milk From the Diet in Functional Dyspepsia: A Cross-sectional Study
Completed NCT03252743 - ICBT for Pain-predominant FGIDs in Children and Adolescents: an Implementation Study. N/A
Completed NCT04697641 - Helicobacter Pylori Eradication in Functional Dyspepsia N/A
Recruiting NCT04918329 - Functional Digestive Disorders Observatory